Research ArticleClinical Investigation

18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus–Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002

Rathan M. Subramaniam, Lyudmila DeMora, Min Yao, Sue S. Yom, Maura Gillison, Jimmy J. Caudell, John Waldron, Ping Xia, Christine H. Chung, Minh Tam Truong, Michelle Echevarria, Jason W. Chan, Jessica L. Geiger, Loren Mell, Samantha Seaward, Wade L. Thorstad, Jonathan Jay Beitler, Khalil Sultanem, Diagjin Blakaj and Quynh-Thu Le
Journal of Nuclear Medicine March 2023, 64 (3) 362-367; DOI: https://doi.org/10.2967/jnumed.122.264424

Article Figures & Data

Tables

  • TABLE 1.

    NPV per Central Review for 2-Year PFS

    PET/CT result and outcomeIMRT + cisplatinIMRTTotal
    PET overall interpretation
     Positive for residual tumor0 (0.0%)2 (3.4%)2 (1.7%)
     Negative for residual tumor57 (100.0%)56 (96.6%)113 (98.3%)
    2-y PFS status in PET-negative
     Failure4 (7.0%)5 (8.9%)9 (8.0%)
     Nonfailure53 (93.0%)51 (91.1%)104 (92.0%)
    NPV of 2-y PFS93.0%91.1%92.0%
     95% exact CI83.0%–98.1%80.4%–97.0%85.4%–96.3%
     One-sided 90% exact LCB86.5%84.1%87.7%
    H0: NPV ≤ 90% vs. HA: NPV > 90%
     P value (exact)0.2964
  • TABLE 2.

    NPV per Central Review for 2-Year LRC

    PET/CT result and outcomeIMRT + cisplatinIMRTTotal
    PET overall interpretation
     Positive for residual tumor0 (0.0%)2 (3.6%)2 (1.8%)
     Negative for residual tumor56 (100.0%)54 (96.4%)110 (98.2%)
    2-y LRC status in PET-negative
     Failure3 (5.4%)3 (5.6%)6 (5.5%)
     Nonfailure53 (94.6%)51 (94.4%)104 (94.5%)
    NPV of 2-y LRC94.6%94.4%94.5%
     95% exact CI85.1%–98.9%84.6%–98.8%88.5%–98.0%
     One-sided 90% exact LCB88.5%88.0%90.6%
    H0: NPV ≤ 90% vs HA: NPV > 90%
     P value (exact)0.0682

Additional Files

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords